Effects of Mesna on Homocysteine in Kidney Failure
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Effects of 12 mg/kg Intravenous Mesna on Plasma Total Homocysteine Concentration in Patients With End-Stage Renal Disease Requiring Hemodialysis|
- Difference in plasma total homocysteine between placebo and mesna treatments [ Time Frame: Four weeks ]
- Excretion of mesna during hemodialysis [ Time Frame: duration of dialytic session ]
|Study Start Date:||March 2007|
|Study Completion Date:||June 2007|
Placebo Comparator: Placebo
Saline IV infusion over five minutes at the beginning of dialysis.
Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
Active Comparator: Mesna
12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
Homocysteine is a thiol amino acid derived from dietary methionine. Elevated plasma total homocysteine (tHcy), termed hyperhomocysteinemia, is a graded, independent risk factor for the development of atherosclerosis. Elevated plasma tHcy can be normalized by supplementation with folic acid and vitamins B6 and B12 in most patients with normal renal function and this treatment has been shown to halt the progression of atherosclerotic plaque.
Over 90% of patients with end-stage renal disease (ESRD) requiring hemodialysis have elevated plasma tHcy. The leading causes of morbidity and mortality in these patients are cardiovascular-related pathologies such as myocardial infarction and stroke. Vitamin supplementation consistently fails to normalize elevated plasma tHcy in patients with ESRD, thus leaving them at increased risk. Plasma tHcy is 70 - 80% covalently protein bound limiting the effectiveness of dialysis as a tHcy lowering treatment.
Mesna (sodium 2-mercaptoethanesulfonic acid) is a thiol-containing drug currently indicated to prevent hemorrhagic cystitis associated with ifosfamide chemotherapy. Mesna has incidentally been shown to deplete plasma thiols in cancer patients undergoing ifosfamide chemotherapy. Mesna acts to exchange with thiols bound to plasma proteins enhancing their renal excretion. In vitro studies in our laboratory have shown that mesna rapidly (within 5 minutes) exchanges with protein bound homocysteine yielding a significantly larger dialyzable fraction of the thiol amino acid.
A pilot study recently completed by our group demonstrated a significant decrease in tHcy in eight hemodialysis patients receiving 12 mg/kg mesna three times a week pre-dialysis for one week. Although this therapy did cause a significant decline in tHcy, mesna failed to reduce tHcy to normal levels. The cumulative effects of mesna administration over a longer treatment period should be evaluated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00524199
|London Health Sciences Centre|
|London, Ontario, Canada, N6A 5A5|
|Principal Investigator:||David J Freeman, MSc, PhD||Lawson Health Research Institute|
|Principal Investigator:||Andrew A House, MD||Lawson Health Research Institute|